



26th ASIA-PACIFIC PROSTATE CANCER CONFERENCE

APCC26

Melbourne Convention & Exhibition Centre, Australia | AUGUST 13-15

Together In Discovery & Care



THE ROLE OF METASTASIS DIRECTED THERAPY IN OLIGOMETASTATIC PROSTATE CANCER: EVIDENCE, INTEGRATION INTO PRACTICE AND FUTURE DIRECTIONS



THURSDAY
13 August, 2026
0830 - 1330

As the treatment landscape for prostate cancer continues to evolve, metastasis directed therapy has emerged as a compelling strategy for managing oligometastatic disease.

This workshop, featuring lectures and case-based debates, will explore the biological rationale, advanced imaging techniques, and clinical trial data shaping the role of metastasis directed therapy in contemporary prostate cancer care.

Attendees will leave with a nuanced, evidence-informed understanding of when, how, and for whom metastasis directed therapy can offer the greatest benefit.

Whether you're a radiation oncologist, urologist, medical oncologist, or imaging specialist, this workshop delivers cutting-edge insights into one of the most promising frontiers in prostate cancer management. Come learn about these aspects, find resources for your location of practice and share your experiences.

FACULTY



Professor Sean Collins
University of South Florida,
United States



A/Professor Giorgio Gandaglia
Vita-Salute San Raffaele University
& IRCCS San Raffaele Hospital, Italy



Professor Oliver Sartor
East Jefferson General Hospital
(EJGH) Cancer Center, United States

WORKSHOP CHAIRS

Dr Phil Dundee & Dr Mario Guerrieri

0830-0845	Welcome
0845-0900	Biological rationale and evidence for metastasis directed therapy A/Prof Marlon Perera, Peter MacCallum Cancer Centre, Melbourne
0900-0915	Optimising patient selection – next generation imaging Prof Rodney Hicks, MTIC, Melbourne
0915-0930	PSMA based radioguided surgery in primary and recurrent prostate cancer A/Prof Giorgio Gandaglia, Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Italy
0930-0945	Rationale for involved site SBRT: Enhanced Intermittent ADT in nodal oligorecurrent prostate cancer Prof Sean Collins, University of South Florida, United States
0945-1000	Real world clinical outcomes – Australian experience Dr Jeremy de Leon, GenesisCare, Sydney
1000-1015	Oligorecurrent nodal prostate cancer metastases: SBRT versus elective whole-pelvic radiotherapy Prof Andrew Kneebone, GenesisCare, Sydney
1015-1030	Question & Answer
1030 - 1100	Morning Tea
1100-1115	The role of systemic therapy in oligometastatic hormone sensitive prostate cancer in the metastasis directed therapy era A/Prof David Pook, Cabrini Health, Melbourne
1115-1130	Metastasis directed therapy in mCRPC Dr Patrick Bowden, ICON Cancer Centre, Melbourne
1130-1145	Radioligand therapy as metastasis directed therapy Prof Oliver Sartor, East Jefferson General Hospital (EJGH) Cancer Center, United States
1145-1245	Case presentations and expert panel Q&A Panel
1245 - 1330	Lunch

[Program correct at time of publication]

FIND OUT MORE

Scan the QR code to learn more about the APCC26 workshops.



For a 10% discount use code UROLOGY10

Proudly sponsored by

